Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252889 · ClinicalTrials.gov registry record · Phase 1
Doxil Topotecan Doublet Cancer Study
A Phase 1 study, sponsored by Christiana Care Health Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00252889 is a Phase 1 study that has completed, run by Christiana Care Health Services. The registered enrollment target is 20 participants.
The verdict
NCT00252889, a Phase 1 study, has completed, sponsored by Christiana Care Health Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective is to determine the nature and degree of the toxicity of weekly dosing of topotecan in escalating dose levels by cohorts of 3-6 patients in combination with a fixed dose of pegylated liposomal doxorubicin (Doxil). The secondary objective is to determine the activity of weekly topotecan and pegylated liposomal doxorubicin in advanced solid tumors.
Interventions
- DRUG Topotecan and pegylated doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-05 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252889
The ClinicalTrials.gov registry entry for NCT00252889 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Christiana Care Health Services, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topotecan and pegylated doxorubicin is the first listed.
NCT00252889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00252889 about?
NCT00252889 is a clinical study titled "Doxil Topotecan Doublet Cancer Study". The primary objective is to determine the nature and degree of the toxicity of weekly dosing of topotecan in escalating dose levels by cohorts of 3-6 patients in combination with a fixed dose of pegylated liposomal doxorubicin (Doxil). The secondary objective is to determine the activity of weekly ...
What is the current status of trial NCT00252889?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2004-05. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00252889?
The interventions under investigation include: Topotecan and pegylated doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00252889?
This trial is sponsored by Christiana Care Health Services, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.